INAL RESEARCH Effectiveness of next-generation sequencing for patients with advanced non-small-cell lung cancer: a population-based registry study

被引:5
|
作者
Kang, D. -W. [1 ]
Park, S. -K. [2 ]
Yu, Y. L. [3 ]
Lee, Y. [4 ]
Lee, D. H. [5 ]
Kang, S. [3 ,6 ,7 ,8 ]
机构
[1] Sungkyunkwan Univ, Sch Pharm, Suwon, South Korea
[2] Catholic Univ Korea, Coll Pharm, Bucheon, South Korea
[3] Natl Canc Ctr, Ctr Gynecol Canc, Res Inst & Hosp, Goyang, South Korea
[4] Natl Canc Ctr, Dept Internal Med, Goyang, South Korea
[5] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[6] Natl Canc Ctr, Grad Sch Canc Sci & Policy, Dept Canc Control & Policy, Goyang, South Korea
[7] Natl Canc Ctr, Res Inst & Hosp, Ctr Gynecol Canc, 323 Ilsan Ro, Goyang Si, Gyeonggi Do, South Korea
[8] Natl Canc Ctr, Grad Sch Canc Sci & Policy, Dept Canc Control & Policy, 323 Ilsan Ro, Goyang Si, Gyeonggi Do, South Korea
关键词
next-generation sequencing; single-gene testing; non-small-cell lung cancer; distant metastasis; real-world evidence;
D O I
10.1016/j.esmoop.2023.102200
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Despite the growing use of next-generation sequencing (NGS) in the management of advanced non-smallcell lung cancer (NSCLC), there is little evidence that its use leads to improved clinical outcomes. This study aimed to compare the effectiveness of NGS with that of single-gene testing (SGT) alone in patients with advanced NSCLC. Materials and methods: This was a retrospective cohort study conducted on patients diagnosed with advanced lung adenocarcinoma between 2017 and 2018 from a nationwide, population-based database. We identified patients who had SGT exclusively (SGT group) or underwent upfront NGS or NGS following SGT as an initial evaluation (NGS group). Patients were followed up until death or the end of the study (31 December 2019). The adjusted hazard ratio (aHR) for death was estimated using the Cox proportional hazards model. The factors affecting the adoption of NGS were identified. Results: Of 8566 patients diagnosed with advanced lung adenocarcinoma, 402 and 6932 patients were assigned to the NGS and SGT groups, respectively. More NGS was carried out in younger patients, those with higher incomes, and those living in urban areas. After balancing these confounders through matching, no difference was observed in the median overall survival and risk of death between the NGS and SGT groups [18.5 versus 19.7 months, log-rank P 1/4 0.783; aHR 0.98, 95% confidence interval (CI) 0.84-1.14, respectively]. Only in a subgroup for whom epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) inhibitors were not indicated, NGS was associated with better survival outcomes (14.1 versus 9.0 months, log-rank P 1/4 0.006; aHR 0.82, 95% CI 0.69-0.97). Conclusions: In the real world, NGS for all-comers in patients with advanced NSCLC did not increase survival outcomes. When health care resources to support equal access to NGS are limited, upfront SGT followed by NGS may be a more efficient strategy
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Next Generation Sequencing-Based Profiling of Cell Free DNA in Patients with Advanced Non-Small Cell Lung Cancer: Advantages and Pitfalls
    Abate, Riziero Esposito
    Frezzetti, Daniela
    Maiello, Monica Rosaria
    Gallo, Marianna
    Camerlingo, Rosa
    De Luca, Antonella
    De Cecio, Rossella
    Morabito, Alessandro
    Normanno, Nicola
    CANCERS, 2020, 12 (12) : 1 - 17
  • [42] Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer
    Wen, Shiwang
    Dai, Lei
    Wang, Lei
    Wang, Wenjian
    Wu, Duoguang
    Wang, Kefeng
    He, Zhanghai
    Wang, Aodi
    Chen, Hui
    Zhang, Peng
    Dong, Xiaowei
    Dong, Yu-An
    Wang, Kai
    Yao, Ming
    Wang, Minghui
    ONCOLOGIST, 2019, 24 (11) : E1070 - E1081
  • [43] A population-based study of gefitinib in patients with non-small cell lung cancer
    Hayashibara, Kenji
    Satoh, Hiroaki
    Shinohara, Yoko
    Inagaki, Masaharu
    Kaburagi, Takayuki
    Hashimoto, Toshio
    Kurishima, Koichi
    Ishikawa, Hiroichi
    Ichimura, Hideo
    Nawa, Takeshi
    Funayama, Yasunori
    Matsumura, Takeshi
    Kagohashi, Katsunori
    Endo, Takeshi
    Furukawa, Kinya
    Kishi, Koji
    Sumi, Masaaki
    Kamiyama, Koichi
    Ishikawa, Shigemi
    MEDICAL ONCOLOGY, 2009, 26 (02) : 222 - 227
  • [44] Molecular Characterization by Next-Generation Sequencing (NGS) of Patients with Non-Small Cell Lung Cancer (NSCLC) Treated with Immunotherapy
    Cruz Castellanos, P.
    Rosas Alonso, R.
    Ozaez, I.
    Hernandez, I.
    Losantos, I.
    Gutierrez Sainz, L.
    Higuera Gomez, O.
    Rodriguez Antolin, C.
    Esteban Rodriguez, I.
    Ibanez de Caceres, I.
    de Castro Carpeno, J.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S558 - S558
  • [45] Repeat Next-Generation Sequencing (15-Gene Panel) in Unifocal, Synchronous, and Metachronous Non-Small-Cell Lung Cancer-A Single-Center Experience
    Kuang, Shelley
    Chen, Kaitlin
    Sayal, Sachin
    Prabahan, Gajeni
    Rabey, Mary R.
    Le, Lisa W.
    Seto, Andrew
    Shepherd, Frances A.
    Liu, Geoffrey
    Bradbury, Penelope
    Sacher, Adrian G.
    Law, Jennifer H.
    Sabatini, Peter
    Stockley, Tracy L.
    Tsao, Ming S.
    Leighl, Natasha B.
    CURRENT ONCOLOGY, 2024, 31 (08) : 4476 - 4485
  • [46] Impact of Molecular Testing Using Next-Generation Sequencing in the Clinical Management of Patients with Non-Small Cell Lung Cancer in a Public Healthcare Hospital
    Simarro, Javier
    Perez-Simo, Gema
    Mancheno, Nuria
    Ansotegui, Emilio
    Munoz-Nunez, Carlos Francisco
    Gomez-Codina, Jose
    Juan, Oscar
    Palanca, Sarai
    CANCERS, 2023, 15 (06)
  • [47] Dynamic ctDNA Assay by Next Generation Sequencing to Guide Targeted Therapy in Advanced Non-Small Cell Lung Cancer
    Liu, D.
    Hou, H.
    Zhou, N.
    Jiang, M.
    Cong, J.
    Zhang, C.
    Li, T.
    Lv, H.
    Zhu, J.
    Hao, C.
    Liu, K.
    Zhang, X.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1908 - S1909
  • [48] Clinical Impact of Next-Generation Sequencing in KRAS-Mutated Non-Small Cell Lung Cancer Patients: a Single-Center Experience
    Anagnostakis, M.
    Panagiotou, E.
    Karachaliou, A.
    Kolintzikis, V.
    Tsamis, I.
    Vathiotis, I. A.
    Syrigos, N. K.
    Nikolaidou, V.
    Papafili, A.
    Kotteas, E.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S485 - S485
  • [49] The Impact of Systemic Treatment on Brain Metastasis in Patients with Non-Small-Cell Lung Cancer: A Nationwide Population-Based Cohort Study
    Ko, Y. H.
    Hong, J. H.
    Sun, D. S.
    Won, H. S.
    Lee, J. S.
    Lee, H. W.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S360 - S361
  • [50] Cost-effectiveness Analysis of the OncomineTM Dx Target Test MultiCDx System Using Next-generation Sequencing and Single-gene Test in Advanced and Recurrent Nonsquamous Non-small-cell Lung Cancer
    Kohara, Tomomi
    Ikeda, Shunya
    Ishikawa, Koichi Benjamin
    JMA JOURNAL, 2024, 7 (03): : 375 - 386